Skip to main content

#Cholera – Multi-country with a focus on countries experiencing current surges (#WHO D.O.N., August 29 '25)

 


{Summary}

Situation at a glance

The global cholera situation continues to deteriorate, driven by conflict and poverty, posing a significant public health challenge across multiple WHO regions. 

Between 1 January and 17 August 2025, a total of 409 222 cholera/Acute Watery Diarrhoea (AWD) cases and 4738 deaths were reported globally, from 31 countries, with six of the 31 countries reporting case fatality rates above 1%, indicating serious gaps in case management and delayed access to care. 

Cholera is resurging in a number of countries, including some that had not reported substantial case numbers in years, like Chad and the Republic of Congo, while other countries, such as the Democratic Republic of the Congo, South Sudan, and Sudan, are experiencing outbreaks that are continuing from 2024, with significant geographic expansion. This complicates containment efforts and strains fragile health systems. 

Conflict, mass displacement, disasters from natural hazards, and climate change have intensified outbreaks, particularly in rural and flood-affected areas, where poor infrastructure and limited healthcare access delay treatment. 

These cross-border factors have made cholera outbreaks increasingly complex and harder to control. 

Safe drinking water, sanitation and hygiene are the only long-term and sustainable solutions to ending this cholera emergency and preventing future ones. 

Given the scale, severity, and interconnected nature of these outbreaks, the risk of further spread within and between countries is considered very high. 

Without urgent and coordinated public health measures, based on:

- strengthened surveillance, 

- improved case management, 

- WASH interventions, 

- vaccination campaigns, and 

- cross-border collaboration, 

cholera transmission is likely to expand across countries. 

WHO collaborates with the Ministries of Health, partners and stakeholders in affected countries. 

WHO supports countries in all pillars of cholera control, including: 

- strengthening epidemiological surveillance, 

- reinforcing laboratory capacity, 

- improving access to and quality of treatment, 

- implementing appropriate WASH and IPC practices, 

- promoting community engagement in cholera prevention and control and 

- facilitating OCV access and campaign implementation. 

On 26 August, the Africa CDC and WHO launched the Continental Cholera Emergency Preparedness and Response Plan for Africa 1.0, alongside a joint Incident Management Team. This initiative follows the commitment of African Heads of State and Government, who have elevated cholera to a continental priority through their recent high-level Call to Action, pledging to control and eliminate outbreaks by 2030.

(...)

Source: World Health Organization, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON579

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...